Atlas Regeneration Inc, a company dedicated to developing novel software platforms and algorithms for drug discovery relating to regenerative medicine and stem cell research, has officially launched. Atlas has partnered with InSilico Medicine, a Baltimore based bioinformatics company, which employs its state of the art Geroscope platform to select and rate personalized anti-aging therapies and identify new drug candidates in longevity.
Aging is an issue that effects all people
around the globe universally, but as the babyboomer generation ages, the
stress that it places on society becomes greater and the need develop
methods for people to remain productive as they age rises in turn. Aging
is a very complex multifactorial process that cannot be stopped or
reversed by a simple combination of drugs, which is why it is important
to develop personalized treatments tailored to individual subjects. The
pharmaceutical industry needs a platform to effectively utilize and
clinically implement stem cells technology.
Another angle the new company is concentrating
on screening and predicting the effectiveness of possible
regeneration-inducing drugs in a high-throughput environment to at least
slow some of the aging processes by stimulating natural tissues
regeneration potential. Some of the known drugs have been on the market
for many decades and only recently have scientists started finding clues
to their anti-inflammation, regeneration and geroprotective effects.
There is an urgent need for intelligent systems that will
cost-effectively predict the effectiveness of the many drugs on
individual tissue, organ and organism levels.
One of the reasons why pharmaceutical
companies failed to develop business models for increasing productive
human longevity and organ regeneration using iPSC technology is because
iPS cells have serious safety and differentiation limitation and it
takes several weeks to evaluate safety and the differentiation potential
of each particular cell line.
Some of the ideas behind the company’s
bioinformatics platforms for both regeneration, iPS and aging are rather
simple: analyze all available omics profiles of “cells-in-progress”
(iPSC line under evaluation, cells/tissues under treatment and so on)
and targeted counterpart cells in mature healthy tissues or organs, run
computer simulations based on proprietary pathway map to see what drugs
or treatments make the old or undifferentiated cell get as close to the
norm/healthy counterparts as possible and then validate the results on
human cells and model organisms. The same approach may be employed to
personalize the drug regimen for individual patients. The core parts of
the technology are proprietary signaling pathway map, a unique scoring
algorithm along with well-developed biological models which allows us to
use all-inclusive gene expression analysis, including microRNA,
methylation and proteomics modules among others, and a comprehensive
constantly updated drug database.
“We built our platform, Regeneration
Intelligence, on years of experience in regenerative medicine and
pharmacology, de novo organ regeneration, body-on-the chip technology
just to mention a few of them with a one single goal: develop a reliable
tool to convert multi-omics data from individual patient’s tissues into
unified drug score to predict the effectiveness of targeted compounds
and improve clinical decision making, unified iPSC lines score to
predict differentiation potential and evaluate clinical safety,” said
Anthony Atala, MD, the CEO of Atlas Regeneration. “We are reinventing
this system for drug discovery in regeneration medicine and aging to
more effectively employ big data to find solutions for aging, competing
with the Google’s Calico and Human Longevity companies, to deliver hope
that we may see the time when our mutual efforts will start saving lives
and increase life span via regeneration in adult humans.”
About Atlas Regeneration Inc
In last couple years the Atlas Regeneration team has worked hard to develop the most advanced pathway analysis algorithm (Regeneration Intelligences) and the most comprehensive scalable drug knowledge management system of annotated drugs, small molecules, biologics and all other actionable factors (Universal Signalome Atlas). For more information, please visit: http://www.AtlasRegeneration.com
No comments:
Post a Comment